Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;19(3):235-253.
doi: 10.5230/jgc.2019.19.e25. Epub 2019 Aug 12.

Clinical Implementation of Precision Medicine in Gastric Cancer

Jaewook Jeon  1 , Jae-Ho Cheong  2   3   4   5   6
Affiliations
Review

Clinical Implementation of Precision Medicine in Gastric Cancer

Jaewook Jeon et al. J Gastric Cancer. 2019 Sep.

Abstract

Gastric cancer (GC) is one of the deadliest malignancies in the world. Currently, clinical treatment decisions are mostly made based on the extent of the tumor and its anatomy, such as tumor-node-metastasis staging. Recent advances in genome-wide molecular technology have enabled delineation of the molecular characteristics of GC. Based on this, efforts have been made to classify GC into molecular subtypes with distinct prognosis and therapeutic response. Simplified algorithms based on protein and RNA expressions have been proposed to reproduce the GC classification in the clinical field. Furthermore, a recent study established a single patient classifier (SPC) predicting the prognosis and chemotherapy response of resectable GC patients based on a 4-gene real-time polymerase chain reaction assay. GC patient stratification according to SPC will enable personalized therapeutic strategies in adjuvant settings. At the same time, patient-derived xenografts and patient-derived organoids are now emerging as novel preclinical models for the treatment of GC. These models recapitulate the complex features of the primary tumor, which is expected to facilitate both drug development and clinical therapeutic decision making. An integrated approach applying molecular patient stratification and patient-derived models in the clinical realm is considered a turning point in precision medicine in GC.

Keywords: Adjuvant chemotherapy; Molecular targeted therapy; Precision medicine; Stomach neoplasm; Tumor biomarkers.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1. Clinical perspectives of patient-derived model systems in precision medicine. (A) PDO and PDX biobanks recapitulating a heterogeneous patient population that facilitateshigh-throughput drug screening and preclinical drug testing respectively. (B) Co-clinical trials were conducted on both the patients as well as the models derived from them, enabling drug response validation and molecular mechanism investigation of response/resistance. (C) Avatar models are established from tumor samples of individual gastric cancer patients. Active drugs are identified using drug screening on avatar models, assisting physicians to optimize anti-cancer treatment.
PDX = patient-derived xenograft; PDO = patient-derived organoid.
Fig. 2
Fig. 2. Clinical implementation of precision medicine in resectable GC. (A) Resected GC samples are subjected to single patient classifier. GC patients are stratified into three subtypes: immune, epithelial, and stem-like. Optimized treatment strategy is arranged for each patient based on the clinical subtype. Immune subtypes receive no additional treatment after surgery, whereas epithelial subtypes are treated with adjuvant chemotherapy and stem-like subtypes are directly enrolled for the clinical trials. (B) High-risk patients are identified by integrating the clinicopathologic data, TNM staging, and molecular subtypes, such as high TNM stage, diffuse histology, stem-like type. Potential target drug screening is conducted on avatar models of high-risk patients to select personalized target drugs for potential cancer recurrence.
mRNA = messenger RNA; RT-PCR = real-time polymerase chain reaction; GC = gastric cancer; FFPE = formalin-fixed, paraffin-embedded tumor tissue; OP = operation; TNM = tumor-node-metastasis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
    1. Jung KW, Won YJ, Kong HJ, Lee ES. Prediction of cancer incidence and mortality in Korea, 2018. Cancer Res Treat. 2018;50:317–323. - PMC - PubMed
    1. Jung KW, Won YJ, Kong HJ, Lee ES Community of Population-Based Regional Cancer Registries. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer Res Treat. 2018;50:303–316. - PMC - PubMed
    1. Jun JK, Choi KS, Lee HY, Suh M, Park B, Song SH, et al. Effectiveness of the Korean national cancer screening program in reducing gastric cancer mortality. Gastroenterology. 2017;152:1319–1328.e7. - PubMed
    1. Kim HH, Han SU, Kim MC, Hyung WJ, Kim W, Lee HJ, et al. Long-term results of laparoscopic gastrectomy for gastric cancer: a large-scale case-control and case-matched Korean multicenter study. J Clin Oncol. 2014;32:627–633. - PubMed